Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity

Molecular Therapy

Volumn 15, Issue 2, 2007, Pages 422-430

  Neal, Zane C ^a   Bates, Mary K ^a   Albertini, Mark R ^b   Herweijer, Hans ^a  

^a Mirus Bio Corporation   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; EPITOPE; GLYCOPROTEIN GP 100; PLASMID DNA; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; GENE TARGETING; HUMORAL IMMUNITY; HYDRODYNAMICS; IN VIVO STUDY; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HINDLIMB; HUMANS; INJECTIONS, INTRAVENOUS; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; VACCINATION; VACCINES, DNA;

ANIMALIA; MURINAE; MUS;

EID: 33846279404     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300046     Document Type: Article

References (44)

1. Houghton, AN, Gold, JS and Blachere, NE (2001). Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13: 134-140.
2. Dyall, R et al. (1998). Heteroclitic immunization induces tumor immunity. J Exp Med 188: 1553-1561.
3. Srinivasan, R and Wolchok, JD. (2004). Tumor antigens for cancer immunotherapy: Therapeutic potential of xenogeneic DNA vaccines. J Transl Med 2: 12.
4. Zhai, Y et al. (1997). Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens mart1 and gp100. J Immunother 20: 15-25.
5. Tanaka, M et al. (2002). Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther 5: 291-299.
6. Gold, JS et al. (2003). A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 170: 5188-5194.
7. Hawkins, WG et al. (2000). Immunization with DNA coding for gp100 results in cd4 t-cell independent antitumor immunity. Surgery 128: 273-280.
8. Rakhmilevich, AL et al. (2001). Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 7: 952-961.
9. Glover, DJ, Lipps, HJ and Jans, DA (2005). Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6: 299-310.
10. Wells, DJ (2004). Opening the floodgates: Clinically applicable hydrodynamic delivery of plasmid DNA to skeletal muscle. Mol Ther 10: 207-208.
11. Hagstrom, JE et al. (2004). A facile nonviral method for delivering genes and sirnas to skeletal muscle of mammalian limbs. Mol Ther 10: 386-398.
12. Toumi, H et al. (2006). Rapid intravascular injection into limb skeletal muscle: A damage assessment study. Mol Ther 13: 229-236.
13. Zhang, G, Budker, V and Wolff, JA (1999). High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 10: 1735-1737.
14. Bates, MK et al. (2006). Genetic immunization for antibody generation in research animals by intravenous delivery of plasmid DNA. Biotechniques 40: 199-208.
15. Overwijk, WW et al. (1998). Gp100/pmel 17 is a murine tumor rejection antigen: Induction of ″self″-reactive, tumoricidal t cells using high-affinity, altered peptide ligand. J Exp Med 188: 277-286.
16. Wang, LX et al. (2005). Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 65: 10569-10577.
17. Overwijk, WW et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive cd8+ t cells. J Exp Med 198: 569-580.
18. Barber, DL, Wherry, EJ and Ahmed, R (2003). Cutting edge: Rapid in vivo killing by memory cd8 t cells. J Immunol 171: 27-31.
19. Yang, S et al. (1999). Murine dendritic cells transfected with human gp100 elicit both antigen-specific cd8(+) and cd4(+) t-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Int J Cancer 83: 532-540.
20. Schreurs, MW, de Boer, AJ, Figdor, CG and Adema, GJ (1998). Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic t lymphocyte-mediated tumor protection. Cancer Res 58: 2509-2514.
21. Yasumoto, K et al. (2004). Epitope mapping of the melanosomal matrix protein gp100 (pmel17): Rapid processing in the endoplasmic reticulum and glycosylation in the early golgi compartment. J Biol Chem 279: 28330-28338.
22. Finn, OJ (2003). Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 3: 630-641.
23. Gilboa, E (2004). The promise of cancer vaccines. Nat Rev Cancer 4: 401-411.
24. Edelstein, ML, Abedi, MR, Wixon, J and Edelstein, RM (2004). Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 6: 597-602.
25. Hacein-Bey-Abina, S et al. (2003). Lmo2-associated clonal t cell proliferation in two patients after gene therapy for scid-x1. Science 302: 415-419.
26. Reid, T, Warren, R and Kirn, D (2002). Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 9: 979-986.
27. Hagstrom, JE (2003). Plasmid-based gene delivery to target tissues in vivo: The intravascular approach. Curr Opin Mol Ther 5: 338-344.
28. Herweijer, H and Wolff, JA (2003). Progress and prospects: Naked DNA gene transfer and therapy. Gene Ther 10: 453-458.
29. Hara, I, Takechi, Y and Houghton, AN (1995). Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein. J Exp Med 182: 1609-1614.
30. Overwijk, WW et al. (1999). Vaccination with a recombinant vaccinia virus encoding a ″self″ antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for cd4(+) t lymphocytes. Proc Natl Acad Sci USA 96: 2982-2987.
31. Vennegoor, C et al. (1988). A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol 130: 179-192.
32. Veiga-Fernandes, H, Walter, U, Bourgeois, C, McLean, A and Rocha, B (2000). Response of naive and memory cd8+ t cells to antigen stimulation in vivo. Nat Immunol 1: 47-53.
33. Antony, PA et al. (2005). Cd8+ t cell immunity against a tumor/ self-antigen is augmented by cd4+ t helper cells and hindered by naturally occurring t regulatory cells. J Immunol 174: 2591-2601.
34. Gattinoni, L et al. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific cd8+ t cells. J Exp Med 202: 907-912.
35. Morel, PA, Falkner, D, Plowey, J, Larregina, AT and Falo, LD (2004). DNA immunisation: Altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 22: 447-456.
36. Corr, M, Lee, DJ, Carson, DA and Tighe, H (1996). Gene vaccination with naked plasmid DNA: Mechanism of ctl priming. J Exp Med 184: 1555-1560.
37. Porgador, A et al. (1998). Predominant role for directly transfected dendritic cells in antigen presentation to cd8+ t cells after gene gun immunization. J Exp Med 188: 1075-1082.
38. Nagaraju, K (2001). Immunological capabilities of skeletal muscle cells. Acta Physiol Scand 171: 215-223.
39. Trubetskoy, VS et al. (2003). Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther 10: 261-271.
40. Rakhmilevich, AL et al. (1996). Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93: 6291-6296.
41. Lanza, F et al. (1997). Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells. Cytometry 30: 134-144.
42. Neal, ZC et al. (2004). Enhanced activity of hu14.18-il2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10: 4839-4847.
43. Bryant, J, Day, R, Whiteside, TL and Herberman, RB (1992). Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146: 91-103.
44. Brehm, MA, Daniels, KA, Ortaldo, JR and Welsh, RM (2005). Rapid conversion of effector mechanisms from nk to t cells during virus-induced lysis of allogeneic implants in vivo. J Immunol 174: 6663-6671.